Peritoneal Cancer

P=N/A, N=35, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

P1/2, N=100, Completed, Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Active, not recruiting --> Completed

Finally, emerging combination strategies involving chemokine blockade together with immune checkpoint inhibitors, metabolic interventions, PARP inhibitors, and ferroptosis-related approaches are evaluated. However, successful clinical translation will require precise patient stratification, effective toxicity management, and validation in clinically annotated cohorts.

P3, N=404, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Initiation date: Apr 2026 --> Jul 2026

P1, N=19, Not yet recruiting, Shanghai Gynecologic Oncology Group

P1, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2027

P2, N=22, Completed, University of Washington | Active, not recruiting --> Completed

Our study identifies the IFN-DAPK3-DCAF1 pathway as a critical post-translational mechanism that ensures rapid ZBP1 stabilization. This highlights a fundamental strategy to bypass transcriptional latency for the rapid activation of immune responses, offering a strong clinical rationale to harness this pathway to induce ZBP1-dependent PANoptosis for the treatment of refractory tumors.

The HRd rate in this Taiwanese cohort aligns with existing literature. PARPi significantly improved survival in HRd patients, but adverse events necessitate careful hematological monitoring for treatment sustainability.

This case underscores the utility of combining CA125 and imaging for early PPC detection in STIC-positive BRCA2 carriers, particularly in older patients. Olaparib may also offer therapeutic benefit.

After neoadjuvant chemotherapy with paclitaxel, carboplatin, and bevacizumab, followed by interval debulking surgery and postoperative chemotherapy, she achieved a complete response and began maintenance therapy with bevacizumab plus olaparib. This case highlights a previously unreported ocular adverse event associated with combined PARP inhibitor and anti-VEGF maintenance therapy. Clinicians should maintain vigilance for visual symptoms and consider periodic ophthalmologic monitoring in patients receiving prolonged olaparib-based therapy.

This case underscores the diagnostic challenges of SM-MPM, particularly in patients presenting with recurrent unexplained ascites and multiple serous effusions. It highlights the importance of maintaining a high index of suspicion and the pivotal role of laparoscopy, immunohistochemistry, and multidisciplinary collaboration in achieving timely diagnosis and optimizing patient outcomes.